
Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.
The pharmaceutical giant reported sales of $23.74 billion, up 5.8% year over year and beating the consensus of $22.85 billion. Operational growth was 4.6%, and adjusted operational growth was 3%.